FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters

Key Points:

• The FDA will hold a meeting in July to consider easing restrictions on seven popular peptide injections, which are unapproved therapies often promoted by wellness influencers and celebrities despite limited safety research.
• Health Secretary Robert F. Kennedy Jr. has advocated for loosening regulations on peptides, citing personal benefits, and the FDA plans to remove these peptides from a restricted list for unapproved high-risk drugs.
• Critics, including former FDA officials and medical experts, warn that allowing peptides without rigorous clinical testing poses significant safety risks and undermines the FDA's drug approval system.
• The peptides under review, such as BPC-157, are widely marketed for injury healing and anti-aging but remain technically illegal to sell as drugs and are banned by international sports authorities.
• The FDA's previous restrictions on peptides faced opposition from wellness entrepreneurs, compounding pharmacies, and some lawmakers, who argue that current limits have fueled an unregulated gray market for these substances.